These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 660216)

  • 1. Treatment of mouse muscular dystrophy with the protease inhibitor pepstatin.
    Schorr EE; Arnason BG; Aström KE; Darzynkiewicz Z
    J Neuropathol Exp Neurol; 1978 May; 37(3):263-8. PubMed ID: 660216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muscular dystrophy: inhibition of degeneration in vivo with protease inhibitors.
    Stracher A; McGowan EB; Shafiq SA
    Science; 1978 Apr; 200(4337):50-1. PubMed ID: 635570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic trials in muscular dystrophy. III. Studies of microbial proteinase inhibitors in murine dystrophy.
    Enomoto A; Bradley WG
    Arch Neurol; 1977 Dec; 34(12):771-3. PubMed ID: 337944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed degeneration of dystrophic and normal muscle cell cultures treated with pepstatin, leupeptin, and antipain.
    McGowan EB; Shafiq SA; Stracher A
    Exp Neurol; 1976 Mar; 50(3):649-57. PubMed ID: 1253868
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of experimental allergic encephalomyelitis with an inhibitor of cathepsin D (pepstatin).
    Boehme DH; Umezawa H; Hashim G; Marks N
    Neurochem Res; 1978 Apr; 3(2):185-94. PubMed ID: 307703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic trial with protease inhibitor (leupeptin) in chicken muscular dystrophy. A histologic and histochemical study.
    Nonaka I; Ishiura S; Takagi A; Sugita H
    Acta Neuropathol; 1982; 58(4):279-85. PubMed ID: 7158305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo effects of protease inhibitors on chickens with hereditary muscular dystrophy.
    Hudecki MS; Pollina CM; Heffner RR
    J Clin Invest; 1981 Apr; 67(4):969-74. PubMed ID: 7204579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The inhibition by pepstatin of cathepsin D and autolysis of dystrophic muscle.
    Iodice AA
    Life Sci; 1976 Nov; 19(9):1351-8. PubMed ID: 11385
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful treatment of murine muscular dystrophy with the proteinase inhibitor leupeptin.
    Sher JH; Stracher A; Shafiq SA; Hardy-Stashin J
    Proc Natl Acad Sci U S A; 1981 Dec; 78(12):7742-4. PubMed ID: 6950412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pepstatin, an inhibitor of acid kininogenases and ascites retardant in neoplastic disease.
    Greenbaum LM
    Fed Proc; 1979 Dec; 38(13):2788-91. PubMed ID: 92421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chymostatin has no apparent beneficial effect on muscular dystrophy in the mdx mouse.
    Christie KN
    J Neurol Sci; 1988 Apr; 84(2-3):341-6. PubMed ID: 3379449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for a defective thiol protease inhibitor in skeletal muscle of mice with hereditary muscular dystrophy.
    Gopalan P; Dufresne MJ; Warner AH
    Biochem Cell Biol; 1986 Oct; 64(10):1010-9. PubMed ID: 3541973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of stretch and denervation on protease activities of normal and dystrophic chicken muscle.
    Lee YB; Ashmore CR; Hitchcock L
    Exp Neurol; 1984 May; 84(2):420-7. PubMed ID: 6714351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effect of chymostatin on dystrophic mice.
    Komatsu K; Matsui A; Satoh S
    Exp Neurol; 1986 Jul; 93(1):110-6. PubMed ID: 3732454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of in vivo inhibition of tissue cathepsin D by pepstatin A.
    Leto G; Tumminello FM; Gebbia N; Rausa L
    Int J Biochem; 1988; 20(9):917-20. PubMed ID: 3197907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastric ulcer therapy with a pepsin-inactivating peptide, pepstatin: a double-blind randomized clinical trial.
    Svendsen LB; Christiansen PM; Bonnevie O
    Scand J Gastroenterol; 1979; 14(8):929-32. PubMed ID: 394302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pepstatin inhibition of rat myocardial acid protease.
    Hokins BE; Smith TW
    Recent Adv Stud Cardiac Struct Metab; 1976 May 26-29; 12():439-43. PubMed ID: 1031998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pepstatins: aspartic proteinase inhibitors having potential therapeutic applications.
    Tumminello FM; Bernacki RJ; Gebbia N; Leto G
    Med Res Rev; 1993 Mar; 13(2):199-208. PubMed ID: 8445958
    [No Abstract]   [Full Text] [Related]  

  • 19. Host cathepsin D response to tumor in the normal and pepstatin-treated mouse.
    Greenbaum LM; Sutherland JH
    Cancer Res; 1983 Jun; 43(6):2584-7. PubMed ID: 6850578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice.
    Ohnishi H; Lin KM; Chu TM
    Cancer Res; 1990 Feb; 50(4):1107-12. PubMed ID: 2297759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.